TBPH — Theravance Biopharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on TBPH
| date | signal | measured base rate |
|---|---|---|
| 2026-03-23 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-03-03 | Quarterly earnings far above their own trend earnings | +0.99% over 21 days · t = 1.65 · n = 881 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-07 | Samaha Eli 10% owner | Open-market sale | 5.6K | 17.17 | 95.5K |
| 2026-07-06 | Samaha Eli 10% owner | Open-market sale | 1.4K | 17.04 | 23.9K |
| 2026-07-01 | Samaha Eli 10% owner | Open-market sale | 37.8K | 17.00 | 642.6K |
| 2026-06-30 | Samaha Eli 10% owner | Open-market sale | 25.0K | 17.13 | 428.8K |
| 2026-06-29 | Samaha Eli 10% owner | Open-market sale | 273.9K | 17.23 | 4.7M |
| 2026-06-19 | Miller Aine SVP, DEV & HEAD OF IRE OFFICE | Grant or award | 18.8K | 0.00 | 0 |
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Open-market sale 10b5-1 plan | 6.7K | 16.39 | 109.1K |
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Open-market sale 10b5-1 plan | 3.3K | 16.39 | 54.6K |
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Open-market sale 10b5-1 plan | 3.3K | 16.38 | 54.5K |
| 2026-06-12 | GRAY SUSANNAH Director | Grant or award | 6.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Madison Avenue Partners, LP | 154.4M | 9.5M |
| Weiss Asset Management LP | 121.0M | 7.5M |
| Newtyn Management, LLC | 78.6M | 4.8M |
| BlackRock, Inc. | 69.7M | 4.3M |
| Irenic Capital Management LP | 44.8M | 2.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 29.0M | 1.8M |
| STATE STREET CORP | 21.1M | 1.3M |
| TWO SIGMA INVESTMENTS, LP | 20.4M | 1.3M |
| GEODE CAPITAL MANAGEMENT, LLC | 18.5M | 1.1M |
| DIMENSIONAL FUND ADVISORS LP | 16.0M | 983.6K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Theravance Biopharma, Inc. (TBPH) filed form 8-K · 2026-08-10 · SEC EDGAR
Ask the AI about TBPH
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →